JP2014517694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517694A5 JP2014517694A5 JP2014512189A JP2014512189A JP2014517694A5 JP 2014517694 A5 JP2014517694 A5 JP 2014517694A5 JP 2014512189 A JP2014512189 A JP 2014512189A JP 2014512189 A JP2014512189 A JP 2014512189A JP 2014517694 A5 JP2014517694 A5 JP 2014517694A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nucleic acid
- acid sequence
- vector
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490450P | 2011-05-26 | 2011-05-26 | |
| US61/490,450 | 2011-05-26 | ||
| PCT/US2012/039897 WO2012162705A2 (en) | 2011-05-26 | 2012-05-29 | Cell and gene based methods to improve cardiac function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517694A JP2014517694A (ja) | 2014-07-24 |
| JP2014517694A5 true JP2014517694A5 (enExample) | 2015-07-16 |
| JP6162104B2 JP6162104B2 (ja) | 2017-07-12 |
Family
ID=47218136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512189A Active JP6162104B2 (ja) | 2011-05-26 | 2012-05-29 | 細胞及び遺伝子に基づく心臓機能改善方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9868937B2 (enExample) |
| EP (1) | EP2714709B1 (enExample) |
| JP (1) | JP6162104B2 (enExample) |
| KR (1) | KR20140035967A (enExample) |
| CN (1) | CN103946230B (enExample) |
| AU (1) | AU2012258525B2 (enExample) |
| BR (1) | BR112013030209A2 (enExample) |
| CA (1) | CA2837322C (enExample) |
| RU (1) | RU2608957C2 (enExample) |
| WO (1) | WO2012162705A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013030209A2 (pt) | 2011-05-26 | 2017-06-13 | Univ Washington | métodos baseados em célula e gene para melhorar função cardíaca |
| EP2792742A1 (en) * | 2013-04-17 | 2014-10-22 | Universitätsklinikum Hamburg-Eppendorf (UKE) | Gene-therapy vectors for treating cardiomyopathy |
| WO2015153357A1 (en) * | 2014-03-29 | 2015-10-08 | Beat Biotherapeutics Corp. | Compositions and methods for improving cardiac function |
| US10479821B2 (en) | 2015-01-16 | 2019-11-19 | University Of Washington | Micro-dystrophins and related methods of use |
| US10646588B2 (en) | 2015-03-11 | 2020-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | RP2 and RPGR vectors for treating X-linked retinitis pigmentosa |
| US10118034B2 (en) * | 2015-08-18 | 2018-11-06 | Boston Scientific Scimed, Inc. | Methods for producing cardiomyocyte cells |
| WO2018144770A1 (en) * | 2017-02-04 | 2018-08-09 | AnaBios Corporation | System and methods for predicting drug-induced inotropic and pro-arrhythmia risk |
| CN108913655B (zh) * | 2018-07-16 | 2022-07-15 | 浙江大学 | 基于多能干细胞技术建立“人源性”心肌肥大模型的方法 |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| KR20210102870A (ko) | 2018-08-30 | 2021-08-20 | 테나야 테라퓨틱스, 인코포레이티드 | 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍 |
| US20200405824A1 (en) * | 2019-06-26 | 2020-12-31 | University Of Washington | Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease |
| CN110384800B (zh) * | 2019-07-19 | 2021-06-08 | 广东省实验动物监测所 | LncRNA XLOC_075168在制备促进血管新生的药物中的应用 |
| BR112022015979A2 (pt) | 2020-02-13 | 2022-10-11 | Tenaya Therapeutics Inc | Vetores de terapia genética para tratamento de doenças cardíacas |
| US20240189481A1 (en) * | 2021-04-06 | 2024-06-13 | University Of Washington | Non-contractile cardiomyocytes for cardiac repair |
| JP2024545507A (ja) * | 2021-12-10 | 2024-12-09 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | Ａａｖベクターを用いたトロポニンｃ（ｔｎｎｃ１）遺伝子治療 |
| WO2025207745A1 (en) * | 2024-03-27 | 2025-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of inducing dilated cardiomyopathy phenotype in cardiomyocytes and applications thereof |
| CN120758566B (zh) * | 2025-09-10 | 2025-11-21 | 瓯江实验室 | 一种在心肌细胞中特异性过表达zer1的病毒载体的构建及在心衰治疗中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02240440A (ja) | 1989-03-14 | 1990-09-25 | Shiigeru:Kk | 慣性ダンパ |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US6151525A (en) * | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
| WO1999062940A2 (en) | 1998-05-30 | 1999-12-09 | Collateral Therapeutics, Inc. | Methods of altering cardiac cell phenotype |
| CA2342283C (en) * | 1998-09-11 | 2004-05-25 | The Regents Of The University Of California | Recombinant adenovirus for tissue specific expression in heart |
| EP1139751A4 (en) * | 1998-12-28 | 2003-03-19 | Arch Dev Corp | EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS |
| AU2002230999A1 (en) * | 2000-12-21 | 2002-07-01 | Medtronic, Inc. | Electrically responsive promoter system |
| AU2003234520A1 (en) * | 2002-05-08 | 2003-11-11 | The Regents Of The University Of California | Methods and compositions for correction of cardiac conduction disturbances |
| US20040161847A1 (en) | 2002-09-11 | 2004-08-19 | Phillips Michael Ian | Vigilant vector system |
| EP1654366A1 (en) | 2003-08-11 | 2006-05-10 | University Of South Florida | Stem cell beacon |
| ATE532863T1 (de) | 2003-11-21 | 2011-11-15 | Daiichi Sankyo Co Ltd | Verfahren zur anzucht von myokardzellen |
| WO2005094485A2 (en) | 2004-03-25 | 2005-10-13 | Yun Yen | Drug screening |
| DE102011018586A1 (de) | 2011-04-26 | 2012-10-31 | Oliver Müller | Vektorsystem zur spezifischen Genexpression im Herzmuskel |
| BR112013030209A2 (pt) | 2011-05-26 | 2017-06-13 | Univ Washington | métodos baseados em célula e gene para melhorar função cardíaca |
-
2012
- 2012-05-29 BR BR112013030209A patent/BR112013030209A2/pt not_active Application Discontinuation
- 2012-05-29 WO PCT/US2012/039897 patent/WO2012162705A2/en not_active Ceased
- 2012-05-29 RU RU2013157590A patent/RU2608957C2/ru not_active IP Right Cessation
- 2012-05-29 CN CN201280034527.5A patent/CN103946230B/zh not_active Expired - Fee Related
- 2012-05-29 EP EP12790042.1A patent/EP2714709B1/en active Active
- 2012-05-29 JP JP2014512189A patent/JP6162104B2/ja active Active
- 2012-05-29 AU AU2012258525A patent/AU2012258525B2/en active Active
- 2012-05-29 US US14/122,226 patent/US9868937B2/en active Active
- 2012-05-29 CA CA2837322A patent/CA2837322C/en active Active
- 2012-05-29 KR KR1020137034630A patent/KR20140035967A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014517694A5 (enExample) | ||
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| IL286926A (en) | Recombinant adeno-associated virus serotype modified peptide between aav9 and aavrh74 with reduced liver tropism and increased muscle transduction | |
| JP2019513393A5 (enExample) | ||
| AR125268A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
| JP2017538401A5 (enExample) | ||
| NZ763018A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| JP2019513399A5 (enExample) | ||
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2014512171A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| WO2015158749A3 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
| MY175477A (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| EP4407035A3 (en) | Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy | |
| JP2017048194A5 (enExample) | ||
| JP2015500002A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| HRP20250541T1 (hr) | Isporuka mikro-distrofina s adeno-povezanim virusnim vektorom za liječenje mišićne distrofije | |
| MX367100B (es) | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. | |
| PE20150163A1 (es) | Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav | |
| EP4378487A3 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| MX2018007234A (es) | Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal. | |
| WO2015081101A8 (en) | Adeno-associated virus vectors for treatment of glycogen storage disease | |
| EA202092589A2 (ru) | Cxcr2-связывающие полипептиды |